Cargando…

Update on the management of inflammatory bowel disease: specific role of adalimumab

Anti-tumor necrosis factor alpha (TNF-α) medications are a class of biologics employed in the treatment of patients with inflammatory bowel disease (IBD). Adalimumab is the first fully human monoclonal immunoglobulin directed against TNF-α, which binds with high affinity and specificity to membrane...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guidi, Luisa, Pugliese, Daniela, Armuzzi, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2011
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3163921/ https://www.ncbi.nlm.nih.gov/pubmed/21904462 http://dx.doi.org/10.2147/CEG.S14558

Ejemplares similares

Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab
por: Armuzzi, Alessandro, et al.
Publicado: (2013)

Predictors and Early Markers of Response to Biological Therapies in Inflammatory Bowel Diseases
por: Privitera, Giuseppe, et al.
Publicado: (2021)

Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches
por: Privitera, Giuseppe, et al.
Publicado: (2021)

Frontiers in Drug Research and Development for Inflammatory Bowel Disease
por: Currò, Diego, et al.
Publicado: (2017)

Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach
por: Corsello, Antonio, et al.
Publicado: (2021)

The management of inflammatory bowel diseases in the era of COVID-19 pandemic: When “non-urgent” does not mean “deferrable”
por: Pugliese, Daniela, et al.
Publicado: (2020)

Paradoxical arthritis occurring during anti-TNF in patients with inflammatory bowel disease: histological and immunological features of a complex synovitis
por: Alivernini, Stefano, et al.
Publicado: (2018)

Adalimumab in Pediatric Inflammatory Bowel Disease
por: Choi, So Yoon, et al.
Publicado: (2022)

Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis
por: Pugliese, Daniela, et al.
Publicado: (2016)

Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre
por: Scaldaferri, Franco, et al.
Publicado: (2020)

TREM1 predicts response to anti-tumor necrosis factor in inflammatory bowel diseases: Towards precision medicine
por: Felice, Carla, et al.
Publicado: (2019)

Nurses are Critical in Aiding Patients Transitioning to Biosimilars in Inflammatory Bowel Disease: Education and Communication Strategies
por: Armuzzi, Alessandro, et al.
Publicado: (2019)

FOXP3(+) T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNFα Agents
por: Guidi, Luisa, et al.
Publicado: (2013)

Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab
por: Pugliese, Daniela, et al.
Publicado: (2022)

Orphan patients with inflammatory bowel disease - when we treat beyond evidence
por: Privitera, Giuseppe, et al.
Publicado: (2021)

Novel Topics in Inflammatory Bowel Disease
por: Sakuraba, Atsushi, et al.
Publicado: (2016)

Cytokines in Spondyloarthritis and Inflammatory Bowel Diseases: From Pathogenesis to Therapeutic Implications
por: Felice, Carla, et al.
Publicado: (2023)

Adalimumab for treatment of very early onset inflammatory bowel disease
por: Xie, Yao, et al.
Publicado: (2019)

Mental Illnesses in Inflammatory Bowel Diseases: mens sana in corpore sano
por: Bartocci, Bianca, et al.
Publicado: (2023)

Lung Involvement in Inflammatory Bowel Diseases: Shared Pathways and Unwanted Connections
por: Cavalli, Carolina Aliai Micol, et al.
Publicado: (2023)

Adalimumab in the management of Behçet’s disease
por: Ueda, Atsuhisa, et al.
Publicado: (2015)

Sphingosine 1-Phosphate Modulation in Inflammatory Bowel Diseases: Keeping Lymphocytes Out of the Intestine
por: Dal Buono, Arianna, et al.
Publicado: (2022)

Diet and Nutrients in Gastrointestinal Chronic Diseases
por: Corsello, Antonio, et al.
Publicado: (2020)

Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars
por: Petric, Zvonimir, et al.
Publicado: (2022)

Incident Colorectal Cancer in Inflammatory Bowel Disease
por: Neri, Benedetto, et al.
Publicado: (2022)

Therapeutic monitoring of adalimumab at non-trough levels in patients with inflammatory bowel disease
por: Kato, Masaichi, et al.
Publicado: (2021)

Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease
por: Vernero, Marta, et al.
Publicado: (2023)

Atherosclerotic cardiovascular diseases in inflammatory bowel diseases: to the heart of the issue
por: Gabbiadini, Roberto, et al.
Publicado: (2023)

Use of thiopurines in inflammatory bowel disease: an update
por: Singh, Arshdeep, et al.
Publicado: (2022)

Hyperbaric oxygen therapy: More hope than hype for future treatment of perianal fistulizing Crohn's disease?
por: Armuzzi, Alessandro, et al.
Publicado: (2022)

Update on current applications of proteomic in the study of inflammatory bowel disease
por: Roda, Giulia, et al.
Publicado: (2012)

The role of small-bowel endoscopy in inflammatory bowel disease: an updated review on the state-of-the-art in 2021
por: Skamnelos, Alexandros, et al.
Publicado: (2021)

An Update on the Role of Extracellular Vesicles in the Pathogenesis of Necrotizing Enterocolitis and Inflammatory Bowel Diseases
por: Filip, Rafał
Publicado: (2021)

Matrix Metalloproteinases in Inflammatory Bowel Disease: An Update
por: O'Sullivan, Shane, et al.
Publicado: (2015)

Technological advances in inflammatory bowel disease endoscopy and histology
por: Alfarone, Ludovico, et al.
Publicado: (2022)

Evaluation of the Predictive Performance of Population Pharmacokinetic Models of Adalimumab in Patients with Inflammatory Bowel Disease
por: Marquez-Megias, Silvia, et al.
Publicado: (2021)

Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics
por: Katsanos, Konstantinos H., et al.
Publicado: (2017)

Genetic and Epigenetic Etiology of Inflammatory Bowel Disease: An Update
por: Jarmakiewicz-Czaja, Sara, et al.
Publicado: (2022)

Cardiovascular implications of inflammatory bowel disease: An updated review
por: Bhardwaj, Arshia, et al.
Publicado: (2023)

An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
por: Zhou, Xin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_qju66mkuvlhcba3b80tp24817l